Medicare cost in matched hospice and non-hospice cohorts.
Hospice care is perceived as enhancing life quality for patients with advanced, incurable illness, but cost comparisons to non-hospice patients are difficult to make. The very large Medicare expenditures for care given during the end of life, combined with the pressure on Medicare spending, make this information important. We sought to identify cost differences between patients who do and do not elect to receive Medicare-paid hospice benefits. We introduce an innovative prospective/retrospective case-control method that we used to study 8,700 patients from a sample of 5% of the entire Medicare beneficiary population for 1999-2000 associated with 16 narrowly defined indicative markers. For the majority of cohorts, mean and median Medicare costs were lower for patients enrolled in hospice care. The lower costs were not associated with shorter duration until death. For important terminal medical conditions, including non-cancers, costs are lower for patients receiving hospice care. The lower cost is not associated with shorter time until death, and appears to be associated with longer mean time until death.
Pyenson
Bruce
B
Milliman, Inc., New York, New York 10119, USA.
Connor
Stephen
S
Fitch
Kathryn
K
Kinzbrunner
Barry
B
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000191:economics / Q000401:mortality / Q000628:therapy; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D017048:Health Care Costs; D006333:Heart Failure / Q000191:economics / Q000401:mortality / Q000628:therapy; D017051:Hospice Care / Q000191:economics*; D006801:Humans; D008297:Male; D006278:Medicare / Q000191:economics*; D008875:Middle Aged; D009369:Neoplasms / Q000191:economics / Q000401:mortality / Q000628:therapy; D020521:Stroke / Q000191:economics / Q000401:mortality / Q000628:therapy; D015996:Survival Rate